Zacks Investment Research upgraded shares of vTv Therapeutics Inc. (NASDAQ:VTVT) from a sell rating to a buy rating in a research report sent to investors on Tuesday. The brokerage currently has $4.75 price target on the biotechnology company’s stock.
According to Zacks, “vTv Therapeutics Inc. is a biopharmaceutical company which is engaged in the discovery and development of orally administered small molecule drug candidates to fill unmet medical needs. Its drug candidate for the treatment of Alzheimers disease includes azeliragon TTP488, which is in Phase III clinical trials; type II diabetes drug candidates include Glucokinase Activator TTP399 and GLP-1r Agonist TTP273 which completed Phase I clinical trials; products for the prevention of muscle weakness and treatment of inflammatory disorders include HPP593, HPP737 and HPP971 which is in Phase1 clinical trials. The Company’s drug discovery platform consists of TTP Translational Technology. vTv Therapeutics Inc. is headquartered in High Point, North Carolina. “
A number of other equities research analysts have also recently commented on VTVT. HC Wainwright set a $13.00 price target on shares of vTv Therapeutics and gave the stock a buy rating in a report on Thursday, May 4th. Canaccord Genuity reaffirmed a buy rating and issued a $15.00 price target on shares of vTv Therapeutics in a report on Friday, August 4th. Five equities research analysts have rated the stock with a buy rating, vTv Therapeutics has an average rating of Buy and an average price target of $14.15.
vTv Therapeutics (VTVT) traded up 5.18% during trading on Tuesday, hitting $4.47. The stock had a trading volume of 36,640 shares. vTv Therapeutics has a 1-year low of $3.57 and a 1-year high of $7.50. The firm has a 50 day moving average price of $4.58 and a 200-day moving average price of $5.28. The firm’s market capitalization is $43.33 million.
vTv Therapeutics (NASDAQ:VTVT) last posted its quarterly earnings results on Wednesday, August 2nd. The biotechnology company reported ($0.41) EPS for the quarter, topping analysts’ consensus estimates of ($0.43) by $0.02. The company had revenue of $0.01 million during the quarter, compared to the consensus estimate of $0.19 million. On average, equities research analysts expect that vTv Therapeutics will post ($1.10) EPS for the current year.
ILLEGAL ACTIVITY NOTICE: This piece of content was first reported by StockNewsTimes and is owned by of StockNewsTimes. If you are viewing this piece of content on another website, it was illegally copied and reposted in violation of United States & international trademark & copyright law. The legal version of this piece of content can be accessed at https://stocknewstimes.com/2017/08/12/vtv-therapeutics-inc-vtvt-upgraded-to-buy-at-zacks-investment-research.html.
Large investors have recently bought and sold shares of the company. Renaissance Technologies LLC boosted its stake in vTv Therapeutics by 24.3% in the fourth quarter. Renaissance Technologies LLC now owns 60,900 shares of the biotechnology company’s stock worth $294,000 after buying an additional 11,901 shares during the period. Candriam Luxembourg S.C.A. acquired a new position in vTv Therapeutics during the first quarter worth $917,000. Essex Investment Management Co. LLC acquired a new position in vTv Therapeutics during the first quarter worth $261,000. Bank of New York Mellon Corp raised its position in vTv Therapeutics by 6.1% in the first quarter. Bank of New York Mellon Corp now owns 22,780 shares of the biotechnology company’s stock worth $149,000 after buying an additional 1,305 shares in the last quarter. Finally, Sphera Funds Management LTD. raised its position in vTv Therapeutics by 50.0% in the first quarter. Sphera Funds Management LTD. now owns 300,000 shares of the biotechnology company’s stock worth $1,965,000 after buying an additional 100,000 shares in the last quarter. 11.12% of the stock is currently owned by institutional investors.
About vTv Therapeutics
vTv Therapeutics Inc is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of orally administered small molecule drug candidates. Its drug candidate for the treatment of Alzheimer’s disease (AD) is azeliragon (TTP488), an orally administered, small molecule antagonist targeting the receptor for advanced glycation endproducts (RAGE), for which it has commenced patient enrollment in a Phase III clinical trial.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for vTv Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for vTv Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.